Resected periampullary adenocarcinoma

5-year survivors and their 6- to 10-year follow-up

Taylor S. Riall, John L. Cameron, Keith D. Lillemoe, Jordan M. Winter, Kurtis A. Campbell, Ralph H. Hruban, David Chang, Charles J. Yeo

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Background: Many studies have reported 5-year survival data after pancreaticoduodenectomy for periampullary adenocarcinoma. This study evaluates 10-year survival in patients surviving 5 years after initial surgery. Methods: We reviewed all patients undergoing pancreaticoduodenectomy for periampullary adenocarcinoma from April 1970 to July 1999 at a single institution. All 5-year survivors were identified, and their subsequent 5-year survival was compared with the actuarial survival of the general population starting at 70 years of age. Results: Nine hundred fifteen patients underwent pancreaticoduodenectomy for periampullary adenocarcinoma. Follow-up was complete on 890 patients. There were 201 (23%) 5-year survivors with a median age of 65 years at initial surgery; 51% were male and 92% were Caucasian. For the 5-year survivors, the carcinoma origin was pancreatic in 46%, ampullary in 25%, distal bile duct in 17%, and duodenal in 12%. For all 5-year survivors, the subsequent 5-year actuarial survival rate was 65%, with a median survival after achieving the 5-year landmark of 7.9 additional years. The subsequent 5-year survival by site of tumor origin was 55% for pancreatic, 66% for ampullary, 74% for bile duct, and 85% for duodenal cancer. For the age-matched population, the 5-year survival rate was 87% (P < .001 when compared with those with all periampullary cancers). Conclusions: While the 5-year survival rate for all patients with resected periampullary adenocarcinoma is only 23%, these data imply that attainment of the 5-year survival landmark carries with it an improved survival for the subsequent 5 years. While the survival rate was less than that of the age-matched population, 65% of 5-year survivors survived 5 more years, bringing them to the 10-year postresection landmark.

Original languageEnglish (US)
Pages (from-to)764-772
Number of pages9
JournalSurgery
Volume140
Issue number5
DOIs
StatePublished - Nov 2006
Externally publishedYes

Fingerprint

Survivors
Adenocarcinoma
Survival
Pancreaticoduodenectomy
Survival Rate
Bile Ducts
Duodenal Neoplasms
Population
Neoplasms
Carcinoma

ASJC Scopus subject areas

  • Surgery

Cite this

Riall, T. S., Cameron, J. L., Lillemoe, K. D., Winter, J. M., Campbell, K. A., Hruban, R. H., ... Yeo, C. J. (2006). Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery, 140(5), 764-772. https://doi.org/10.1016/j.surg.2006.04.006

Resected periampullary adenocarcinoma : 5-year survivors and their 6- to 10-year follow-up. / Riall, Taylor S.; Cameron, John L.; Lillemoe, Keith D.; Winter, Jordan M.; Campbell, Kurtis A.; Hruban, Ralph H.; Chang, David; Yeo, Charles J.

In: Surgery, Vol. 140, No. 5, 11.2006, p. 764-772.

Research output: Contribution to journalArticle

Riall, TS, Cameron, JL, Lillemoe, KD, Winter, JM, Campbell, KA, Hruban, RH, Chang, D & Yeo, CJ 2006, 'Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up', Surgery, vol. 140, no. 5, pp. 764-772. https://doi.org/10.1016/j.surg.2006.04.006
Riall TS, Cameron JL, Lillemoe KD, Winter JM, Campbell KA, Hruban RH et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 2006 Nov;140(5):764-772. https://doi.org/10.1016/j.surg.2006.04.006
Riall, Taylor S. ; Cameron, John L. ; Lillemoe, Keith D. ; Winter, Jordan M. ; Campbell, Kurtis A. ; Hruban, Ralph H. ; Chang, David ; Yeo, Charles J. / Resected periampullary adenocarcinoma : 5-year survivors and their 6- to 10-year follow-up. In: Surgery. 2006 ; Vol. 140, No. 5. pp. 764-772.
@article{2e0e70fb3a494e889ed039e8b705909e,
title = "Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up",
abstract = "Background: Many studies have reported 5-year survival data after pancreaticoduodenectomy for periampullary adenocarcinoma. This study evaluates 10-year survival in patients surviving 5 years after initial surgery. Methods: We reviewed all patients undergoing pancreaticoduodenectomy for periampullary adenocarcinoma from April 1970 to July 1999 at a single institution. All 5-year survivors were identified, and their subsequent 5-year survival was compared with the actuarial survival of the general population starting at 70 years of age. Results: Nine hundred fifteen patients underwent pancreaticoduodenectomy for periampullary adenocarcinoma. Follow-up was complete on 890 patients. There were 201 (23{\%}) 5-year survivors with a median age of 65 years at initial surgery; 51{\%} were male and 92{\%} were Caucasian. For the 5-year survivors, the carcinoma origin was pancreatic in 46{\%}, ampullary in 25{\%}, distal bile duct in 17{\%}, and duodenal in 12{\%}. For all 5-year survivors, the subsequent 5-year actuarial survival rate was 65{\%}, with a median survival after achieving the 5-year landmark of 7.9 additional years. The subsequent 5-year survival by site of tumor origin was 55{\%} for pancreatic, 66{\%} for ampullary, 74{\%} for bile duct, and 85{\%} for duodenal cancer. For the age-matched population, the 5-year survival rate was 87{\%} (P < .001 when compared with those with all periampullary cancers). Conclusions: While the 5-year survival rate for all patients with resected periampullary adenocarcinoma is only 23{\%}, these data imply that attainment of the 5-year survival landmark carries with it an improved survival for the subsequent 5 years. While the survival rate was less than that of the age-matched population, 65{\%} of 5-year survivors survived 5 more years, bringing them to the 10-year postresection landmark.",
author = "Riall, {Taylor S.} and Cameron, {John L.} and Lillemoe, {Keith D.} and Winter, {Jordan M.} and Campbell, {Kurtis A.} and Hruban, {Ralph H.} and David Chang and Yeo, {Charles J.}",
year = "2006",
month = "11",
doi = "10.1016/j.surg.2006.04.006",
language = "English (US)",
volume = "140",
pages = "764--772",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Resected periampullary adenocarcinoma

T2 - 5-year survivors and their 6- to 10-year follow-up

AU - Riall, Taylor S.

AU - Cameron, John L.

AU - Lillemoe, Keith D.

AU - Winter, Jordan M.

AU - Campbell, Kurtis A.

AU - Hruban, Ralph H.

AU - Chang, David

AU - Yeo, Charles J.

PY - 2006/11

Y1 - 2006/11

N2 - Background: Many studies have reported 5-year survival data after pancreaticoduodenectomy for periampullary adenocarcinoma. This study evaluates 10-year survival in patients surviving 5 years after initial surgery. Methods: We reviewed all patients undergoing pancreaticoduodenectomy for periampullary adenocarcinoma from April 1970 to July 1999 at a single institution. All 5-year survivors were identified, and their subsequent 5-year survival was compared with the actuarial survival of the general population starting at 70 years of age. Results: Nine hundred fifteen patients underwent pancreaticoduodenectomy for periampullary adenocarcinoma. Follow-up was complete on 890 patients. There were 201 (23%) 5-year survivors with a median age of 65 years at initial surgery; 51% were male and 92% were Caucasian. For the 5-year survivors, the carcinoma origin was pancreatic in 46%, ampullary in 25%, distal bile duct in 17%, and duodenal in 12%. For all 5-year survivors, the subsequent 5-year actuarial survival rate was 65%, with a median survival after achieving the 5-year landmark of 7.9 additional years. The subsequent 5-year survival by site of tumor origin was 55% for pancreatic, 66% for ampullary, 74% for bile duct, and 85% for duodenal cancer. For the age-matched population, the 5-year survival rate was 87% (P < .001 when compared with those with all periampullary cancers). Conclusions: While the 5-year survival rate for all patients with resected periampullary adenocarcinoma is only 23%, these data imply that attainment of the 5-year survival landmark carries with it an improved survival for the subsequent 5 years. While the survival rate was less than that of the age-matched population, 65% of 5-year survivors survived 5 more years, bringing them to the 10-year postresection landmark.

AB - Background: Many studies have reported 5-year survival data after pancreaticoduodenectomy for periampullary adenocarcinoma. This study evaluates 10-year survival in patients surviving 5 years after initial surgery. Methods: We reviewed all patients undergoing pancreaticoduodenectomy for periampullary adenocarcinoma from April 1970 to July 1999 at a single institution. All 5-year survivors were identified, and their subsequent 5-year survival was compared with the actuarial survival of the general population starting at 70 years of age. Results: Nine hundred fifteen patients underwent pancreaticoduodenectomy for periampullary adenocarcinoma. Follow-up was complete on 890 patients. There were 201 (23%) 5-year survivors with a median age of 65 years at initial surgery; 51% were male and 92% were Caucasian. For the 5-year survivors, the carcinoma origin was pancreatic in 46%, ampullary in 25%, distal bile duct in 17%, and duodenal in 12%. For all 5-year survivors, the subsequent 5-year actuarial survival rate was 65%, with a median survival after achieving the 5-year landmark of 7.9 additional years. The subsequent 5-year survival by site of tumor origin was 55% for pancreatic, 66% for ampullary, 74% for bile duct, and 85% for duodenal cancer. For the age-matched population, the 5-year survival rate was 87% (P < .001 when compared with those with all periampullary cancers). Conclusions: While the 5-year survival rate for all patients with resected periampullary adenocarcinoma is only 23%, these data imply that attainment of the 5-year survival landmark carries with it an improved survival for the subsequent 5 years. While the survival rate was less than that of the age-matched population, 65% of 5-year survivors survived 5 more years, bringing them to the 10-year postresection landmark.

UR - http://www.scopus.com/inward/record.url?scp=33750469380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750469380&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2006.04.006

DO - 10.1016/j.surg.2006.04.006

M3 - Article

VL - 140

SP - 764

EP - 772

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 5

ER -